Abstract: A compound represented by general formula (I) or a pharmaceutically acceptable salt or a stereoisomer thereof, and a use thereof in treating diseases such as tumors, immunological diseases, and inflammatory diseases, as well as a pharmaceutical preparation and a pharmaceutical composition of the compound, and a use thereof.

Abstract: The present invention provides a pluripotent stem cell or a derivative thereof. A first nucleic acid molecule is introduced into a genome of the pluripotent stem cell or the derivative thereof; and a second nucleic acid molecule is introduced to a 3?UTR region of an immune response-related gene in the pluripotent stem cell or the derivative thereof. The first nucleic acid molecule encodes a small nucleic acid molecule that mediates RNA interference, and the small nucleic acid molecule can specifically bind to a transcript product of the second nucleic acid molecule to start an RNA interference program to degrade or silence mRNA of the immune response-related gene, thereby blocking the expression of the immune response-related gene, such that the cell has immunological compatibility, and thus can eliminate or reduce alloimmune rejection responses.

Abstract: Provided is an immunologically compatible and reversible universal pluripotent stem cell or a derivative thereof. An inducible gene expression system and the expression sequence of at least one immunologically compatible molecule are introduced into the genome of the pluripotent stem cell or the derivative thereof. The immunologically compatible molecule is used to regulate the expression of immune response-related genes in the pluripotent stem cell or the derivative thereof. The expression of the immunologically compatible molecule is regulated by the inducible gene expression system. The described method can increase the immunological compatibility between a transplant and a recipient, and can simultaneously reversibly restore the antigen-presenting abilities of transplant cells.

Abstract: The present disclosure relates to a voice shopping method, device, and a computer-readable storage medium, and relates to the field of voice recognition technology. The method includes: receiving a query instruction from a user by voice, and performing semantic recognition on the query instruction to determine one or more keywords of query content of the user; determining a search range of the keywords according to one or more shopping behavior records of the user; searching the keywords within the search range to obtain commodity information related to the query content, and performing voice output; and receiving an ordering instruction from the user by voice, and performing semantic recognition on the ordering instruction to determine whether an order is made.

Abstract: The present disclosure relates to a voice shopping method, device, and a computer-readable storage medium, and relates to the field of voice recognition technology. The method includes: receiving a query instruction from a user by voice, and performing semantic recognition on the query instruction to determine one or more keywords of query content of the user; determining a search range of the keywords according to one or more shopping behavior records of the user; searching the keywords within the search range to obtain commodity information related to the query content, and performing voice output; and receiving an ordering instruction from the user by voice, and performing semantic recognition on the ordering instruction to determine whether an order is made.

Abstract: The present invention relates to a non-viral iPSCs induction method as well as the compositions, kits and iPSCs obtained therefrom. More specifically, the induction method comprises the following steps: 1) Constructing a recombinant plasmid by introducing the DNA sequences expressing the reprogramming factors POU5F1, SOX2, GLIS1, KLF4, MYCL and hsa-miR-302s into an episomal vector; 2) Obtaining iPSCs by introducing the recombinant plasmids obtained in step 1) into human somatic cells, and reprogramming induction culture of the cells. The method reduces the risk of clinical applications of iPSCs by using a combination of highly-safe reprogramming factors without the introduction of high-risk reprogramming factors such as c-MYC, SV40-LT and TP53 inhibitors; The method is highly applicable.

Abstract: The present invention relates to a non-viral iPSCs induction method as well as the compositions, kits and iPSCs obtained therefrom. More specifically, the induction method comprises the following steps: 1) Constructing a recombinant plasmid by introducing the DNA sequences expressing the reprogramming factors POU5F1, SOX2, GLIS1, KLF4, MYCL and hsa-miR-302s into an episomal vector; 2) Obtaining iPSCs by introducing the recombinant plasmids obtained in step 1) into human somatic cells, and reprogramming induction culture of the cells. The method reduces the risk of clinical applications of iPSCs by using a combination of highly-safe reprogramming factors without the introduction of high-risk reprogramming factors such as c-MYC, SV40-LT and TP53 inhibitors; The method is highly applicable.

Abstract: Provided are a culture medium for preparing neural stem cell and use thereof, the culture medium for preparing neural stem cell comprising: a basic culture medium suitable for the growth of stem cell, and a cell signal pathway inhibitor selected from at least one of GSK inhibitor, MEK inhibitor, TGF-? inhibitor, ROCK inhibitor and BMP inhibitor.

Abstract: The present invention relates to a non-viral iPSCs induction method as well as the compositions, kits and iPSCs obtained therefrom. More specifically, the induction method comprises the following steps: 1) Constructing a recombinant plasmid by introducing the DNA sequences expressing the reprogramming factors POU5F1, SOX2, GLIS1, KLF4, MYCL and hsa-miR-302s into an episomal vector; 2) Obtaining iPSCs by introducing the recombinant plasmids obtained in step 1) into human somatic cells, and reprogramming induction culture of the cells. The method reduces the risk of clinical applications of iPSCs by using a combination of highly-safe reprogramming factors without the introduction of high-risk reprogramming factors such as c-MYC, SV40-LT and TP53 inhibitors; The method is highly applicable.

Abstract: The present invention relates to a non-viral iPSCs induction composition and the kits thereof. Specifically, it comprises a recombinant plasmid, and the recombinant plasmid is obtained by constructing the DNA sequences expressing the reprogramming factors POU5F1, SOX2, GLIS1, KLF4, MYCL and hsa-miR-302s into an episomal vector; The DNA sequence of hsa-miR-302s comprises one or more sequences selected from hsa-miR-302a, hsa-miR-302b, hsa-miR-302c and hsa-miR-302d. The induction composition is suitable for a highly safe and non-integrated induction reprogramming to obtain iPSCs, which reduces the risk of the clinical applications without an introduction of the high-risk reprogramming factors such as c-MYC, SV40-LT and TP53 inhibitors.

Abstract: Provided are a culture medium for preparing neural stem cell and use thereof, the culture medium for preparing neural stem cell comprising: a basic culture medium suitable for the growth of stem cell, and a cell signal pathway inhibitor selected from at least one of GSK inhibitor, MEK inhibitor, TGF-? inhibitor, ROCK inhibitor and BMP inhibitor.